Julie Lindgård Graversen

Julie Lindgård Graversen

Auto-generated profile, based on publicly available information

Julie Lindgård Graversen

Steno Diabetes Center North Denmark, Aalborg University Hospital, Hospitalsbyen 4, 9260 Gistrup, Denmark; Department of Clinical Medicine, Aalborg University, Selma Lagerloefs Vej 249, 9260 Gistrup, Denmark

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2022 in EXCLI Journal
Verified
Journal Article
Open access
JNJulie Lindgård Nielsen
Julie Lindgård Nielsen
JKJesper Karmisholt
Jesper Karmisholt
IPInge Bülow Pedersen
Inge Bülow Pedersen
ACAllan Carlé
Allan Carlé
The aim of this study is to evaluate the adequacy of treatment, and to identify factors influencing treatment of hypothyroidism. Patients newly diagnosed with overt hypothyroidism (n=345) were identified via a register linked to a laboratory database. In selected periods with staff available, 165 patients were invited, and 113 (68.5 %) accepted participating in a comprehensive program including blood tests and completion of questionnaires. We performed a longitudinal follow-up on thyroid function tests 10 years after the diagnosis. Time to reach a serum TSH level of 0.2-10 mU/L (termed as clinically acceptable) and biochemical normalization (TSH: 0.2-5.0 mU/L), respectively, were analyzed using Kaplan Meier survival analysis. Predictors for longer duration to reach the normal TSH range were identified using cox proportional hazards regression. Only 67.7 % of the patients were in the euthyroid range on the long term after diagnosis of overt hypothyroidism (2 years: 59.4 %; 10 years: 67.7 %). Median time to the first normal TSH was 8.9 months (95 % CI: 7.6-10.2 months). The factors associated with longer duration until normalization of TSH after multivariate analysis were age (HR 0.79 per 10 years; 95 % CI: 0.66-0.94; P = <0.01), smoking (HR 0.47; 95 % CI: 0.26-0.83; P = <0.01), serum TSH at diagnosis (HR 0.96 per 10 mU/L; 95 % CI: 0.93-0.99; P = 0.02) and BMI (HR 0.96 per kg/m2; 95 % CI: 0.91-0.99; P = 0.03). A considerable number of hypothyroid patients remained inadequately treated. When treating hypothyroid patients, special attention should be addressed to those patients who never or lately obtain euthyroid status.

1 May 2026 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
MMMia Daugaard Madsen
Mia Daugaard Madsen
DADeilany Arulanandam
Deilany Arulanandam
CSChristina Lavín Svendsen
Christina Lavín Svendsen
SPSofie Weisbjerg Rytter Pedersen
Sofie Weisbjerg Rytter Pedersen
JGJulie Lindgård Graversen
Julie Lindgård Graversen
NRNicklas H. Rasmussen
Nicklas H. Rasmussen
To examine postural control in people with type 2 diabetes mellitus (T2DM) with and without diabetic neuropathy (DN) using center of pressure (CoP) measures under varying sensory and cognitive conditions. In this cross-sectional study, adults aged ≥ 40 years with T2DM for at least one year. Neuropathy was classified as severe peripheral neuropathy (DPN) or autonomic neuropathy (DAN), defined by vibration perception threshold ≥ 50 V, ≥2 abnormal cardiac autonomic reflex tests, or orthostatic hypotension. Postural control was assessed by CoPArea and CoPVelocity under different sensory and cognitive conditions. Regression analyses were adjusted for demographic factors, physical performance, and fall-associated medication. Exploratory analyses were performed by neuropathy subtype. 99 participants were included, 49 with DN and 50 without. The DN group was older (66.8 vs. 60.8 years) and more often male (75.5% vs. 52%). DN was associated with greater CoPArea (β = 0.56, p = 0.006). Exploratory analyses suggested larger CoPArea in participants with DAN alone (β = 0.76, 95% CI 0.36-1.16) or combined with DPN (β = 0.70, 95% CI 0.13-1.34), whereas DPN alone was not associated with CoPArea. DN was linked to impaired postural control, with indications of differences by neuropathy subtype. CoP assessment may help identify people with T2DM at increased risk of falls.

14 November 2026 in Osteoporosis International
Verified
Journal Article
Closed access
JGJulie L. Graversen
Julie L. Graversen
AKAnnika Vestergaard Kvist
Annika Vestergaard Kvist
MSMarie B. Sjogaard
Marie B. Sjogaard
MMMia D. Madsen
Mia D. Madsen
NRNicklas H. Rasmussen
Nicklas H. Rasmussen
JRJohan Røikjer
Johan Røikjer

12 October 2026 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
JGJulie L. Graversen
Julie L. Graversen
AKAnnika Vestergaard Kvist
Annika Vestergaard Kvist
MSMarie B. Sjogaard
Marie B. Sjogaard
MMMia D. Madsen
Mia D. Madsen
NRNicklas H. Rasmussen
Nicklas H. Rasmussen
JRJohan Røikjer
Johan Røikjer